Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial

We examined whether baseline dialysate calcium concentration or the serum–dialysate calcium gradient modified the effect of cinacalcet on the following adjudicated endpoints: (1) primary composite endpoint (death or first non‐fatal myocardial infarction, hospitalization for unstable angina, heart failure, or peripheral vascular event); (2) cardiovascular death; and (3) sudden death. In EVOLVE, use of higher dialysate calcium concentrations was more prevalent in Europe and Latin America compared with North America. There was a significant fall in serum calcium concentration in the cinacalcet group; dialysate calcium concentrations were changed infrequently in both groups. There was no association between baseline dialysate calcium concentration or serum–dialysate calcium gradient and the endpoints examined. Neither the baseline dialysate calcium nor the serum–dialysate calcium gradient significantly modified the effects of cinacalcet on the outcomes examined. The effects of cinacalcet on cardiovascular death and major cardiovascular events are not altered by the dialysate calcium prescription and serum–dialysate calcium gradient.

Source: Hemodialysis International - October 1, 2015 Category: Hematology Authors: Patrick H. Pun, Safa Abdalla, Geoffrey A. Block, Glenn M. Chertow, Ricardo Correa‐Rotter, Bastian Dehmel, Tilman B. Drüeke, Jürgen Floege, William G. Goodman, Charles A. Herzog, Gerard M. London, Kenneth W. Mahaffey, Sharon M. Moe, Patrick S. Parfrey, Tags: Original Article Source Type: research